Leslie Wetherell

Leslie Wetherell, Executive Director, Program Strategy, Rare Disease and Pediatrics, is a clinical research professional with over 25 years of global drug development experience, with a focus in rare disease. In her role, Leslie’s therapeutic and operational expertise supports biotech and pharmaceutical companies to achieve key results in rare disease and pediatric studies. Her focus is producing strategic efficiencies that support patient-centric and timely program delivery.

She has extensive phase 1-3 experience in rare disease, oncology, hematology, and general medicine and is accomplished in gaining market/FDA approvals, having led seven phase 3 FDA-approved products over the course of her career.

Leslie joined the Premier team in her current role in 2023. Prior to her tenure with Premier, her past roles have included data management, project management, procurement, and global strategy development positions.